The average number of personnel employed by the entity during a period.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard
-URIDate 2025-03-27

General information - Corporate Information (Details) € in Thousands, $ in Millions				12 Months Ended
	Oct. 06, 2025 EUR (€)	Oct. 06, 2025 USD ($)	Jan. 30, 2025 USD ($)	Dec. 31, 2025 EUR (€) employee vaccine shares	Dec. 31, 2024 EUR (€) employee shares	Dec. 31, 2023 EUR (€) employee	Apr. 09, 2025 participant	Mar. 26, 2025 USD ($)
Disclosure Of General Information [Line Items]
Number of commercial vaccines \| vaccine				3
Average number of employees \| employee				694	695	684
Number of shares issued (in shares) \| shares				9,333,332	23,000,000
Issue of equity				€ 27,435	€ 61,180
Share issue related cost				1,239	4,041
Principal repayment				€ 171,632	€ 3,734	€ 2,097
ATM Program
Disclosure Of General Information [Line Items]
Number of shares issued (in shares) \| shares				9,300,000
Issue of equity				€ 27,400
Share issue related cost				€ 1,200
Pharmakon loan agreement due 2030
Disclosure Of General Information [Line Items]
Borrowing facilities, maximum borrowing capacity \| $		$ 500.0
Undrawn borrowing facilities \| $		285.0
Amended debt financing agreement due 2028
Disclosure Of General Information [Line Items]
Principal repayment	€ 183,000	$ 215.0
Ordinary shares \| ATM Program
Disclosure Of General Information [Line Items]
ATM program, maximum offering amount \| $								$ 75.0
Number of shares represented by one depositary receipt (in shares)								2
IXCHIQ
Disclosure Of General Information [Line Items]
Percentage of participants				97.00%
IXIARO® \| United states (U.S.) department of defense (DoD)
Disclosure Of General Information [Line Items]
Partnership, maximum amount to be released under contract \| $			$ 32.8
Partnership, term			1 year
KENYA \| Shigella
Disclosure Of General Information [Line Items]
number of participants \| participant							110